| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43ae3c128eb0df9db0b7cadfd586f3b0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-27 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27 |
| filingDate |
2016-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f20f5835284722b2270133cc9d1b9384 |
| publicationDate |
2017-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017007711-A1 |
| titleOfInvention |
Pegylated growth hormone antagonists |
| abstract |
A composition that is a human growth hormone receptor antagonist comprising human growth hormone receptor antagonist G120K, wherein at least one amino acid of human growth hormone receptor antagonist G120K has been mutated to cysteine; and a polytethylene glycol molecule (PEG) conjugated to each cysteine residue in the human growth hormone receptor antagonist G120K mutant. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111601818-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3893919-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023028430-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020123450-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019125002-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3983002-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021506934-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023085176-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019211842-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7175983-B2 |
| priorityDate |
2015-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |